Middling Pharma Ltd 13064063 false 2024-01-01 2024-12-31 2024-12-31 The principal activity of the company is Joint Venture Holding company Digita Accounts Production Advanced 6.30.9574.0 true true 13064063 2024-01-01 2024-12-31 13064063 2024-12-31 13064063 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-12-31 13064063 bus:OrdinaryShareClass2 bus:CumulativeRedeemableShares 2024-12-31 13064063 core:CurrentFinancialInstruments 2024-12-31 13064063 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 13064063 core:LandBuildings core:OwnedOrFreeholdAssets 2024-12-31 13064063 bus:SmallEntities 2024-01-01 2024-12-31 13064063 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 13064063 bus:FilletedAccounts 2024-01-01 2024-12-31 13064063 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13064063 bus:RegisteredOffice 2024-01-01 2024-12-31 13064063 bus:Director1 2024-01-01 2024-12-31 13064063 bus:Director2 2024-01-01 2024-12-31 13064063 bus:OrdinaryShareClass1 bus:CumulativeShares 2024-01-01 2024-12-31 13064063 bus:OrdinaryShareClass2 bus:CumulativeRedeemableShares 2024-01-01 2024-12-31 13064063 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13064063 bus:Agent1 2024-01-01 2024-12-31 13064063 core:LandBuildings 2024-01-01 2024-12-31 13064063 core:OtherPropertyPlantEquipment 2024-01-01 2024-12-31 13064063 countries:England 2024-01-01 2024-12-31 13064063 2023-12-31 13064063 core:CostValuation 2023-12-31 13064063 core:LandBuildings core:OwnedOrFreeholdAssets 2023-12-31 13064063 2023-01-01 2023-12-31 13064063 2023-12-31 13064063 bus:OrdinaryShareClass1 bus:CumulativeShares 2023-12-31 13064063 bus:OrdinaryShareClass2 bus:CumulativeRedeemableShares 2023-12-31 13064063 core:CurrentFinancialInstruments 2023-12-31 13064063 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 13064063 core:LandBuildings core:OwnedOrFreeholdAssets 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 13064063

Middling Pharma Ltd

Unaudited Filleted Financial Statements

for the Year Ended 31 December 2024

 

Middling Pharma Ltd

Contents

Company Information

1

Accountants' Report

2

Balance Sheet

3

Notes to the Unaudited Financial Statements

4 to 9

 

Middling Pharma Ltd

Company Information

Directors

Mr Kimberley Thonger

Isabel Jane Thonger

Registered office

3rd Floor
166 College Road
Harrow
Middlesex
HA1 1BH

Accountants

MG Group (Professional Services) Limited
Chartered Accountants166 College Road
Harrow
Middlesex
HA1 1BH

 

Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
Middling Pharma Ltd
for the Year Ended 31 December 2024

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Middling Pharma Ltd for the year ended 31 December 2024 as set out on pages 3 to 9 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of Middling Pharma Ltd, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of Middling Pharma Ltd and state those matters that we have agreed to state to the Board of Directors of Middling Pharma Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Middling Pharma Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Middling Pharma Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Middling Pharma Ltd. You consider that Middling Pharma Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Middling Pharma Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

MG Group (Professional Services) Limited
Chartered Accountants
166 College Road
Harrow
Middlesex
HA1 1BH

23 September 2025

 

Middling Pharma Ltd

(Registration number: 13064063)
Balance Sheet as at 31 December 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

568,567

568,567

Investments

5

1

1

Other financial assets

6

6,827,971

6,108,604

 

7,396,539

6,677,172

Current assets

 

Debtors

7

225,246

225,246

Investments

8

25,000

25,000

Cash at bank and in hand

 

5,047,595

8,150,809

 

5,297,841

8,401,055

Creditors: Amounts falling due within one year

9

(88,620)

(5,197)

Net current assets

 

5,209,221

8,395,858

Total assets less current liabilities

 

12,605,760

15,073,030

Provisions for liabilities

(183,955)

-

Net assets

 

12,421,805

15,073,030

Capital and reserves

 

Called up share capital

10

202

202

Retained earnings

12,421,603

15,072,828

Shareholders' funds

 

12,421,805

15,073,030

For the financial year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 23 September 2025 and signed on its behalf by:
 

.........................................
Mr Kimberley Thonger
Director

 

Middling Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
3rd Floor
166 College Road
Harrow
Middlesex
HA1 1BH
England

These financial statements were authorised for issue by the Board on 23 September 2025.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The financial statements have been prepared on a going concern basis.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable from the investment in and letting of land and property and other investment activities, which are exempt from VAT.

Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

 

Middling Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Land and buildings

Not depreciated

Artworks

Not depreciated

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.


Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

 

Middling Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 1 (2023 - 1).

 

Middling Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

4

Tangible assets

Land and buildings
£

Total
£

Cost or valuation

At 1 January 2024

568,567

568,567

At 31 December 2024

568,567

568,567

Depreciation

Carrying amount

At 31 December 2024

568,567

568,567

At 31 December 2023

568,567

568,567

Included within the net book value of land and buildings above is £568,567 (2023 - £568,567) in respect of freehold land and buildings.
 

5

Investments

2024
£

2023
£

Investments in joint ventures

1

1

Joint ventures

£

Cost

At 1 January 2024

1

Carrying amount

At 31 December 2024

1

At 31 December 2023

1

 

Middling Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

6

Other financial assets (current and non-current)

Financial assets at fair value through profit and loss
£

Total
£

Non-current financial assets

Cost or valuation

At 1 January 2024

6,108,604

6,108,604

Additions

3,425,272

3,425,272

Disposals

(3,289,374)

(3,289,374)

Fair value adjustments

583,469

583,469

At 31 December 2024

6,827,971

6,827,971

The fixed assets investment was valued by the investment company on 31 December 2004, based on the closing share prices traded on the stock market that day.

7

Debtors

Current

Note

2024
£

2023
£

Amounts owed by related parties

11

225,246

225,246

   

225,246

225,246

8

Current asset investments

2024
£

2023
£

Other investments

25,000

25,000

 

Middling Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2024

9

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Taxation and social security

82,585

-

Accruals and deferred income

6,000

4,800

Other creditors

35

397

88,620

5,197

10

Share capital

Allotted, called up and fully paid shares

2024

2023

No.

£

No.

£

Ordinary shares of £1 each

101

101

101

101

Ordinary shares B of £1 each

101

101

101

101

202

202

202

202

11

Related party transactions

Directors

At the balance sheet date, the amount due to the directors was £35 (2023 - £397).

Joint venture company

At the balance sheet date, the amount due from the joint venture company was £225,246 (2023 - £225,246).